United StatesLastništvo in razvrstitev
Ustanovljeno: 2015
Lastništvo
STAT (tudi STAT News) je ameriška zdravstvena, medicinska in življenjska znanstvena novica, ki jo je 4. novembra 2015 začel John W. Henry, lastnik The Boston Globe.
Financiranje
Sprva je bila brezplačna, od takrat pa je STAT poleg oglaševanja, sponzoriranih dogodkov in konferenc, ki jih financira zasebna skupina Boston Globe Media, zgradila tudi poslovanje z plačano naročnino (STAT +).
Pripadnost in usmeritev
STAT nima nobenih strank, državnih ali cerkvenih vezi in deluje kot neodvisna komercialna redakcija, osredotočena na zdravje in biotehnologijo, v zasebni lasti Boston Globe Media Johna Henryja.
Uredniški nagib
- Naša ocena
- Sredina
- Izmerjeno iz poročanja
- Sredinana podlagi 141
73/100
Dejstva
74/100
Objektivnost
240
Članki
240
poročil
Najpomembnejše
Trenutno najbolj pokrito
Mnenje: Odločitev vrhovnega sodišča o Roundupu kaže na zmedo med zakonom in znanostjo
Potrjeni primeri ebole v Kongu so na vrhu 1000 s 254 smrtnimi primeri, pravijo oblasti
Luigi Mangione je preklical lastne odvetnike z 'spreminjanjem srca' na psiho obrambo, pravi pravni strokovnjak
Demokratske države tožijo Medicaid zaradi delovnih pravil.
Nara Organics je po izbruhu botulizma pri otrokih večih držav povzročil povrat izdelka otroškega mleka, ki ga prodajajo v Targetu
Zvezna trgovinska komisija toži vodilno transspolno zdravstveno skupino.
FDA odobri prvi nov sestavni del sončnega krema v več kot 20 letih.
Odbor FDA priporoča mRNA cepivo proti gripi Moderna za starejše odrasle
STAT+: Cadence zbira 100 milijonov dolarjev za avtomatizacijo oskrbe s kroničnimi boleznimi z regulirano AI
Nedavno poročanje
Tri stvari, ki jih je treba opazovati med Antropicovim najnovejšim sporom z vlado
Anthropic, podjetje za umetno inteligenco s sedežem v ZDA, je razvilo napredni model umetne inteligence, imenovan Mythos, ki je pokazal izjemne zmogljivosti pri ravnanju s kodo. Zaradi zaskrbljenosti zaradi morebitnih tveganj za kibernetsko varnost je Anthropic delil omejen dostop s strokovnjaki za kibernetsko varnost, preden je javno izdal spremenjeno različico, imenovano Fable. Vendar pa je ameriška vlada hitro intervenirala, navedla je nacionalne varnostne pomisleke in uvedla izvozne omejitve za Fable. Anthropic je nato preklical dostop do obeh modelov. Ta incident je sprožil razprave o širših posledicah regulacije umetne inteligence, nekateri pa trdijo, da je bil vladni odziv preveč reaktiven, ne pa dobro načrtovan. Poleg tega je dogodek sprožil vprašanja o zanesljivosti ameriških podjetij za umetno inteligenco, kar je spodbudilo evropske voditelje, da razmislijo o pospeševanju lastnih prizadevanj za razvoj umetne inteligence. Medtem so modeli z odprtim virom iz Kitajske pridobili pozornost zaradi njihove dostopnosti in dostopnosti, ki lahko vplivajo na globalne strategije umetne inteligence.
Rojen v ZDA: Varovanje pravice do rojstnega državljanstva
Članek razpravlja o pravnem konceptu državljanstva po rojstvu v Združenih državah, kot je opisano v 14. amandmaju ustave. V članku je navedeno, da je vsakdo, ki se rodi v ZDA, razen otrok diplomatov ali vdanih sil, samodejno državljan. Profesorka Amanda Frost pojasnjuje, da besedilo amandmaja pušča malo prostora za razlago. Vendar pa javno mnenje ostaja razdeljeno, saj približno polovica Američanov podpira podelitev državljanstva otrokom nedokumentiranih priseljencev, druga polovica pa temu nasprotuje.
Mnenje: Vodstvo CDC še naprej skuša izmisliti znanstveno razpravo o cepivih, kjer jih ni
Ta mnenje kritizira Centri za nadzor in preprečevanje bolezni (CDC) za domnevno spodkopavanje lastnih znanstvenih procesov v zvezi z učinkovitostjo cepiva. Avtor poudarja nedavni dogodek "Public Health Grand Rounds", ki ga je gostila CDC, ki se je osredotočil na metodologije za merjenje učinkovitosti cepiva v realnih okoljih. Med sejo so znanstvenik CDC Carrie Reed in drugi razložili standardni pristop, znan kot testno-negativna zasnova, ki primerja posameznike, ki so bili pozitivni na bolezen, s tistimi, ki niso. Avtor trdi, da je vodstvo CDC, vključno z Jayom Bhattacharyajem, sprejelo ukrepe, ki naj bi ovirali preglednost, kot je blokiranje objave notranjih študij o učinkovitosti cepiva.
STAT+: Medicare takes another swing at 340B cuts to hospitals
Medicare has proposed reducing payments to hospitals for drugs purchased through the 340B drug discount program by over a third starting next year. This comes after Medicare's surveys indicated that some patients were paying more for these drugs than the hospitals did. Under the new proposal, Medicare would reimburse hospitals at the average sales price of the drugs minus 33.4%, significantly lower than the current rate of that price plus 6%. The proposal is part of a broader rule on hospital outpatient payments and has sparked controversy, with nonprofit and academic hospitals criticizing it for potentially harming safety-net providers. These hospitals are the only ones eligible for the 340B program, while for-profit hospitals would see a 7.4% pay increase under the same adjustment.
STAT+: Pharmalittle: We’re reading about Chinese trial sites being probed, RFK Jr. and peptides, and more
A bipartisan group of U.S. lawmakers has launched national security investigations into major pharmaceutical companies' clinical trials in China, focusing on potential contributions to China's military capabilities. The inquiry asks companies to detail their due diligence and data protection measures, especially in Xinjiang and military hospitals. Separately, FDA scientists have stated there's insufficient evidence to permit certain peptides to be made by compounding pharmacies, challenging Health Secretary Robert F. Kennedy Jr.'s efforts to expand access to these wellness products. The FDA's stance contrasts with Kennedy's push, as his department adds new panel members with ties to peptide businesses and clinics.
Zyn je varnejši od kajenja.
U.S. Food and Drug Administration (FDA) je pooblastil Philip Morris International (PMI), proizvajalca Zyn nikotinskih vrečk, da prodaja 20 svojih izdelkov z trditvijo o spremenjenem tveganju, ki navaja, da jih namesto cigaret uporablja zmanjšuje tveganje za več resnih bolezni, vključno z rakom ust, srčnimi boleznimi in rakom pljuč.
STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals
A bipartisan group of U.S. Congress members has written to the Department of Health and Human Services, requesting that Eli Lilly be compelled to resume providing discounted drug prices to participating hospitals under the 340B program. The pharmaceutical company ceased these discounts in June 2026, citing concerns over 'duplicate discounts' and stating that many hospitals had not shared required claims data. Lilly reportedly targeted 50 large hospital systems out of around 1,000 that had not adhered to a new policy implemented earlier in the year. The company claimed that over 70% of the 2,300+ hospitals in the program had already submitted the necessary information.
STAT+: Elevance sues government over $115 million tied to Medicare Advantage star ratings
Elevance Health, a major health insurer, has filed a lawsuit against the U.S. government, claiming that the Centers for Medicare & Medicaid Services (CMS) recalculated its Medicare Advantage quality ratings in a manner inconsistent with a recent court ruling. This discrepancy, according to Elevance, has resulted in a financial loss of $115 million. The lawsuit was filed in the U.S. District Court for the Southern District of Georgia and highlights ongoing tensions within the Medicare Advantage program, where private insurers provide alternatives to traditional Medicare. Star ratings, used to assess the quality of care and customer service, determine whether plans receive additional taxpayer funds and rebates. The case underscores broader disputes over regulatory compliance and financial implications for healthcare providers.
STAT+: Gor in dol po lestvici: najnovejše prihodke in odhodke
Članek razpravlja o nedavnih kadrovskih spremembah v farmacevtski industriji, poudarja pa zaposlitev Roberta Hollingswortha kot glavnega znanstvenega uradnika pri Protillion Biosciences.
STAT+: Kaj pomeni izguba DeGettea za farmacevtsko industrijo?
Članek razpravlja o posledicah poraza predstavnice Louise Slaughter (DeGette) na volitvah leta 2024 za farmacevtsko industrijo.
STAT+: AI scientist company Edison Scientific tapped by team behind Metsera to create new biotechs
Edison Scientific, a spin-off from AI science company FutureHouse, has secured $70 million in venture funding to develop AI-driven tools for accelerating scientific discovery. Founded in 2023 by Sam Rodriques and Andrew White, FutureHouse initially focused on creating autonomous AI agents to aid researchers. After receiving significant interest from major pharmaceutical companies seeking to leverage their technology, the founders decided to launch Edison Scientific as a separate entity in late 2025. The article highlights the growing demand for AI in drug discovery and biomedical research, noting that some industry leaders view these AI agents as superior to alternatives like those developed by OpenAI or Anthropic.
Republican Tom Kean Jr. reveals depression diagnosis after his four-month absence from Congress
Republican Congressman Tom Kean Jr. of New Jersey revealed during a congressional speech that he has been undergoing treatment for depression, which explains his four-month absence from the House. Kean, who last voted on March 5, returned to the chamber after winning an uncontested primary in June. He described depression as a serious illness affecting both body and mind, and emphasized that recovery timelines vary. While Kean expressed optimism about returning to work, he did not provide specific details about his medical journey or current status. His reappearance raised questions about the impact of his absence on legislative efforts, particularly for House Republicans struggling with a narrow majority. Kean's district, which includes President Trump's Bedminster golf club, is a politically competitive area, with Democrats targeting it as a potential gain. Kean faces Democratic challenger Rebecca Bennett in November, and both Republican Speaker Mike Johnson and Trump have publicly supported his candidacy.
Dr. Oz je GLP-1 most lahko deluje, vendar to ni model za nadzor cen
Članek razpravlja o programu Medicare GLP-1 Bridge, ki ga je predstavil dr. Oz, ki upravičenim upravičencem Medicare dela D omogoča dostop do nekaterih zdravil GLP-1 za 50 dolarjev na mesec od 1. julija 2025 do 31. decembra 2027. Program vključuje zdravila, kot so Wegovy, Zepbound in Foundayo za hujšanje.
Spregledano
Premalo ali enostransko
